The study, published in Food Science of Animal Resources, used a whey-derived milk polar lipid concentrate containing at least 25 percent total phospholipids, including sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine. Male C57BL/6J mice, a standard strain in metabolic research, were divided into four groups of six animals each. One group received a standard control diet, a second received a high-fat high-sucrose diet deriving 43 percent of its calories from fat and 24 percent from sucrose, a third received that same obesogenic diet modified so that milk fat was replaced with 8 percent of the milk polar lipid concentrate, and a fourth received the obesogenic diet supplemented with 0.01 percent orlistat, the pancreatic lipase inhibitor sold commercially as Xenical, serving as a positive control. The animals were followed for twelve weeks, with body weight and food intake recorded weekly and body composition assessed by dual-energy X-ray absorptiometry shortly before the study’s end.

The results were striking. Mice on the high-fat high-sucrose diet gained substantially more weight than controls, but the animals receiving milk polar lipids ended the study at a final body weight statistically indistinguishable from the normal-diet group. Fat mass, measured by DEXA scanning, was significantly lower in the supplemented animals, and the treatment partially restored lean mass while also improving bone mineral content, an intriguing secondary observation that suggests the lipids may help preserve skeletal status under metabolic stress. Food and calorie intake rose gradually in the unsupplemented high-fat group, but the researchers attributed this to increasing body mass rather than heightened appetite, noting that intake did not differ across groups during the early weeks when body weights were still comparable.

Blood chemistry told a similar story of protection. The obesogenic diet drove up total cholesterol and low-density lipoprotein cholesterol, both well-established indicators of dysregulated lipid metabolism, and elevated alanine aminotransferase and aspartate aminotransferase, the two enzymes clinicians rely on most heavily to detect liver cell damage. Supplementation with the milk lipid concentrate pushed all of these markers back toward normal levels. Serum triglycerides, curiously, were actually higher in the supplemented group than in the unsupplemented high-fat group, but the authors interpret this not as a metabolic failure but as a sign of enhanced lipid mobilization and export from liver and fat stores into circulation, consistent with prior evidence that dietary phospholipids influence very-low-density lipoprotein assembly and hepatic lipid handling. They caution that the relatively short four-hour fast before tissue collection may have introduced postprandial effects and call for future studies measuring free fatty acids and hepatic VLDL secretion rates to clarify the point.

Under the microscope, the differences were unmistakable. Adipocytes in the high-fat group were markedly enlarged, a hallmark of adipose tissue dysfunction that fuels chronic low-grade inflammation and floods peripheral organs with excess free fatty acids. Both the milk lipid and orlistat groups showed significantly smaller adipocytes and reduced weights of inguinal and mesenteric white adipose tissue depots. In the liver itself, hematoxylin and eosin staining and Oil Red O staining revealed heavy fat infiltration in the high-fat group, while the supplemented animals showed dramatically reduced steatosis, lower liver weights, and significantly reduced hepatic triglyceride content. Earlier work had suggested that milk phospholipids partly work by interfering with micellar lipid solubilization in the intestine, reducing absorption and increasing fecal lipid excretion, but the tiny amounts of intact phospholipids recovered in feces in prior studies indicated the supplements themselves are efficiently absorbed, hinting that they must also act systemically after uptake.

That systemic action is where the new study makes its most technically interesting contribution. The researchers probed the hepatic Wnt/β-catenin pathway, an evolutionarily ancient signaling cascade best known for orchestrating embryonic development but increasingly recognized as a metabolic regulator. The obesogenic diet significantly suppressed key components of the pathway, reducing hepatic expression of the co-receptor LRP6 and the ligand Wnt3a. Supplementation with the milk lipids, and to a comparable degree orlistat, restored LRP6 and Wnt3a expression, but only the milk lipid diet significantly upregulated total β-catenin, the pathway’s central transcriptional effector. When Wnt signaling is active, stabilized β-catenin enters the nucleus and suppresses adipogenic transcriptional programs driven by PPARγ and C/EBPα, thereby limiting lipid storage. Consistent with that model, the supplemented animals showed significantly reduced expression of PPARγ and its downstream partners DGAT1 and PLIN2, which govern triglyceride synthesis and lipid droplet formation, along with reduced SREBP1 and the de novo lipogenesis enzymes ACC, SCD1, and FAS.

The authors propose a plausible biophysical explanation for how dietary lipids could touch this membrane-anchored pathway. Polar lipids can alter the composition of cellular membranes, and membrane phosphoinositide metabolism is known to be essential for LRP6 activation, with prior work showing that Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Milk fat globule membrane supplementation has also been shown in lipidomic studies to enrich membranes in phosphatidylcholine and phosphatidylethanolamine. In other words, the phospholipids consumed in the diet may be incorporated into hepatic membranes in ways that sensitize the Wnt machinery, though the authors are careful to frame this as a plausible mechanism rather than a demonstrated one. Notably, milk-derived sphingomyelin has previously outperformed egg-derived sphingomyelin against hepatic steatosis, suggesting that the source and molecular composition of dietary lipids matter in ways the field is only beginning to map.

The second arm of the mechanism involves the gut microbiome, and here the study employed 16S rRNA gene sequencing of cecal contents processed through the DADA2 and QIIME pipelines. The obesogenic diet significantly reduced microbial alpha diversity, as measured by the Shannon index and phylogenetic diversity, and shifted the community structure into a cluster clearly separated from controls. The milk lipid group formed its own distinct cluster, separate from both the high-fat and orlistat groups, with PERMANOVA confirming significant separation between the supplemented and unsupplemented high-fat animals. Because the orlistat group’s microbiome remained similar to the high-fat group’s, the authors infer that the lipids’ microbial effects extend beyond simple inhibition of fat absorption. At the phylum level, supplementation partially reversed the diet-driven rise in Bacillota and boosted Verrucomicrobiota, the phylum housing Akkermansia muciniphila, a mucin-degrading bacterium celebrated for its associations with gut barrier integrity and metabolic health, and consistently depleted in patients with fatty liver disease and obesity.

Additional taxa shifts reinforced the picture. The high-fat diet enriched bile acid-resistant Lactobacillus and Limosilactobacillus species, a pattern previously linked to altered intestinal bile acid composition in fatty liver models, while the milk lipid diet selectively increased Akkermansia along with Romboutsia and members of the Christensenellaceae family, taxa reported to improve lipid metabolism partly through enhanced short-chain fatty acid production. Prior studies have shown that A. muciniphila supplementation attenuates hepatic steatosis and inflammation, modulates bile acid metabolism through the intestinal FXR-FGF15 axis, and enhances mitochondrial fatty acid oxidation via L-aspartate signaling along the gut-liver axis. The authors are appropriately measured about causality, emphasizing that their microbial findings show association rather than proof and that future work measuring microbial metabolites such as short-chain fatty acids and bile acids will be needed to close the loop.

Taken together, the study sketches a coordinated mechanism in which a single dietary component acts simultaneously on intracellular lipogenic signaling and on the ecology of the gut, offering a template for how food-derived bioactives might be engineered into functional ingredients for metabolic disease. The caveats are real: the work was conducted in mice, the intervention used a concentrated extract at a dose that would be difficult to translate directly to human diets, and the mechanistic links remain partly inferential. But with fatty liver disease affecting hundreds of millions of people and no approved pharmacological therapy for its early stages, the idea that the humble membrane lipids enveloping fat droplets in milk could simultaneously quiet a liver’s fat-building program and cultivate a healthier gut community is precisely the kind of convergent finding that could shape the next generation of nutritional interventions.

Subject of Research: Effects of dietary milk polar lipids on hepatic lipid accumulation, Wnt-PPARγ signaling, and gut microbiota in a mouse model of non-alcoholic fatty liver disease

Article Title: Dietary milk polar lipids ameliorate hepatic lipid accumulation through coordinated regulation of Wnt-PPARγ signaling and remodeling of the gut microbiota

Article References: Kim, H., Park, D., Kwon, Y.-J., & Imm, J.-Y. (2026). Dietary milk polar lipids ameliorate hepatic lipid accumulation through coordinated regulation of Wnt-PPARγ signaling and remodeling of the gut microbiota. Food Science of Animal Resources, 46(1), Article 83. https://doi.org/10.1007/s44463-026-00100-w

Image Credits: AI Generated

DOI: 10.1007/s44463-026-00100-w

Keywords: milk polar lipids, non-alcoholic fatty liver disease, Wnt/beta-catenin signaling, PPARgamma, gut microbiota, Akkermansia muciniphila, sphingomyelin, hepatic steatosis, short-chain fatty acids, gut-liver axis, high-fat high-sucrose diet, milk fat globule membrane

That suspicion has been fueled by a striking clinical observation. Reduced GLO1 expression has been reported both in experimental models of metabolic dysfunction-associated fatty liver disease, or MAFLD, and in liver biopsies from patients with the condition. MAFLD, driven by excessive fat storage in the liver, is estimated to affect roughly 24 percent of the United States population and is present in more than 70 percent of patients with type 2 diabetes, making it one of the most common and consequential comorbidities of the modern obesity pandemic. Sustained consumption of high-carbohydrate diets, particularly those rich in fructose, is a major driving factor in the pathogenesis of both obesity and MAFLD, and fructose-containing foods are capable of inducing insulin resistance in humans and metabolic syndrome in mice. Yet despite the clear association between diminished GLO1 and fatty liver disease, a fundamental question remained unanswered: is the loss of GLO1 a cause of the disease, or merely a compensatory response to it?

A new study published in Physiological Reports by a team at the University of Arizona set out to resolve this question directly. Rather than merely observing correlations, the researchers generated whole-body Glo1 knockout mice using CRISPR-SpCas9 genome editing in the C57Bl/6NN strain, targeting exon 3 of the Glo1 gene with guide RNAs to produce frameshift deletions through non-homologous end joining. They then challenged these mice, alongside wild-type controls, with sixteen weeks of a high-fat, high-sucrose diet containing 36 percent fat and 30 percent sucrose, a regimen well documented to induce fatty liver disease and impair glucose tolerance. The team’s initial hypothesis was straightforward: if reduced GLO1 expression contributes to MAFLD, then deleting the gene should exacerbate metabolic dysfunction by increasing MGO-mediated stress. What they found instead was a surprise that reshapes how the field should think about the glyoxalase system.

Contrary to expectations, the knockout mice were substantially protected from hepatic fat accumulation. When wild-type mice consumed the obesogenic diet, they developed substantial hepatic steatosis, with triglycerides building up in the liver as expected. In the Glo1-deficient mice fed the same diet, this triglyceride accumulation was significantly blunted. The protection was specific to the liver: adipose tissue biology was largely unaffected, with no significant differences in adipocyte size, epididymal white adipose tissue mass, or markers of fat tissue injury between genotypes under the high-fat, high-sucrose conditions. Serum triglycerides and beta-hydroxybutyrate, a readout of fatty acid oxidation, varied only with diet and not with genotype, suggesting that the hepatic phenotype was not secondary to altered fat export or whole-body fat burning. The findings point toward a previously unrecognized role for GLO1 in directly regulating hepatic lipid metabolism, positioning the enzyme as an unexpected participant in the biology of fatty liver rather than a passive bystander.

But the metabolic ledger did not balance cleanly. While the knockout mice enjoyed relative protection from fatty liver, their systemic glucose handling deteriorated in a diet-dependent manner. Fasting blood glucose was significantly elevated in high-fat, high-sucrose-fed knockout mice compared with their wild-type counterparts. Oral glucose tolerance testing revealed a significant reduction in the ability of knockout mice to clear systemic glucose when compared with chow-fed controls, and although the difference between the two genotypes on the obesogenic diet did not reach statistical significance in the raw tolerance curves, a deeper analysis told a more troubling story. The constant of glucose decay, calculated from insulin tolerance testing as the rate of glucose disappearance, revealed a significant reduction in insulin responsiveness specifically in the high-fat, high-sucrose-fed knockout mice. Notably, serum insulin levels and hepatic insulin signaling, assessed through phosphorylation of the insulin receptor and AKT, showed no significant differences, indicating that the glucose defect operates independently of measurable changes in insulin activity.

To understand the biochemistry underlying these divergent phenotypes, the researchers turned to sensitive mass spectrometry-based quantification of MGO and its downstream molecular footprints. Free hepatic MGO was not significantly elevated in any treatment group, and the product of GLO1 activity, lactoylglutathione, was significantly reduced in the knockout mice, consistent with the loss of enzyme function. A complicating factor emerged, however: the high-fat, high-sucrose diet produced a marked reduction in hepatic glutathione regardless of genotype, and because glutathione is required for GLO1 activity, the reduction in lactoylglutathione may partly reflect this glutathione depletion. When the team examined MGO-derived post-translational modifications on proteins, the results were equally nuanced. Levels of MGO-hydroimidazolone 1, a signature MGO-derived arginine modification, were not significantly affected by diet or genotype, while carboxyethylarginine was elevated in chow-fed knockout mice. These data contradict previous reports indicating dramatic elevations in MGO-derived modifications under diet-induced metabolic stress, and they suggest that steady-state MGO biology in vivo is more buffered than cell culture experiments would predict.

The study also delivered a decisive verdict on a long-standing controversy in diabetes research. Earlier work using short hairpin RNA to knock down Glo1 reported that reduced GLO1 activity could spontaneously generate pathologies resembling diabetic nephropathy in non-diabetic mice, fueling the idea that GLO1 loss is a primary driver of diabetic kidney disease. The Arizona team therefore reasoned that sixteen weeks of high-fat, high-sucrose feeding would exacerbate kidney injury in their knockout animals. Instead, they found no evidence of renal pathology attributable to GLO1 loss. Kidney glycogen accumulated with the obesogenic diet but was unaffected by genotype, serum urea and creatinine were unchanged across all cohorts, and renal levels of MGO-hydroimidazolone 1, carboxyethylarginine, and 3-nitrotyrosine, a modification associated with oxidative stress, showed no significant differences. These findings independently confirm earlier reports from a separate group that complete genetic deletion of Glo1 fails to reproduce the diabetic kidney phenotype seen with knockdown approaches, and they collectively indicate that loss of GLO1 alone is insufficient to drive diabetic nephropathy.

Why might deleting a detoxification enzyme protect the liver while harming glucose control? The authors offer several mechanistic possibilities grounded in their own prior work. In cultured fibroblasts, they previously showed that loss of GLO1 reduces glucose uptake and glycolytic flux, and that Glo1-deficient cells fail to differentiate into mature adipocytes. If a similar reduction in glycolytic flux occurs in the livers of knockout mice in vivo, it would limit the substrate available for MGO generation, potentially explaining why free MGO and MGO-derived modifications remain largely unchanged despite the absence of the primary detoxification enzyme. Reduced glycolytic flux could also directly limit de novo lipogenesis, the pathway by which the liver converts excess carbohydrate into fat, providing a plausible mechanism for the blunted hepatic triglyceride accumulation. Meanwhile, the concept that MGO is not simply a toxin but a concentration-dependent metabolic signal is gaining traction: modest elevations of MGO have been reported to be protective in cardiac ischemia-reperfusion injury and even stimulatory for tumor growth, while only cytotoxic concentrations far exceeding those measured in vivo cause cell death.

The authors are careful to note the limitations of their work. The dietary intervention was terminated at sixteen weeks, a timepoint at which significant hepatic steatosis is evident but more advanced features of MAFLD, such as frank inflammation and fibrosis, have not yet developed. Whether GLO1 influences disease progression at later stages, including the transition to metabolic dysfunction-associated steatohepatitis, remains unknown and is a focus of ongoing investigation. The study also focused on male mice, leaving potential sex differences unexplored, and it did not evaluate alternative MGO detoxification pathways, such as the aldehyde dehydrogenases and aldose reductase, which are thought to play secondary roles but could become important under chronic metabolic stress. Samples for insulin signaling analysis were collected from fed rather than fasted mice, so the effect of GLO1 on glucose-stimulated insulin secretion could not be assessed.

Even with these caveats, the study carries a clear and provocative message: hepatic lipid accumulation and systemic glycemic control are mechanistically distinct in the absence of GLO1, and the glyoxalase system sits at an unexpected crossroads between the two. For a field that has largely treated MGO as a toxic metabolic accident and GLO1 as a straightforward protective enzyme, the demonstration that complete GLO1 loss limits fatty liver while impairing glucose handling in obese male mice demands a more sophisticated view. Future investigations aimed at deciphering the tissue-specific roles of GLO1 in whole-body glucose tolerance and lipid metabolism may reveal whether the glyoxalase cycle, long relegated to the footnotes of biochemistry textbooks, holds therapeutic potential for one of the most common liver diseases of our time.

Subject of Research: The role of glyoxalase 1 in obesity-associated fatty liver disease, glucose homeostasis, and kidney health in mice.

Article Title: Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice

Article References: Hoffman, E. A., Phoebe, A. M., Trujillo, M. N., Zhang, W. C., Jennings, E. Q., Farrera, D. O., Orlicky, D. J., Rutt, L. N., McCullough, R. L., Huacachino, A. A., Marcinkiewicz, M. M., Snyder, N. W., Bruner, K. R., Payan, K. B., Martinez, D. J. F., Stern, J. H., & Galligan, J. J. (2026). Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice. Physiological Reports, 14(17), Article e71106. https://doi.org/10.14814/phy2.71106

Image Credits: AI Generated

DOI: 10.14814/phy2.71106

Keywords: glyoxalase 1, methylglyoxal, fatty liver disease, MAFLD, glucose tolerance, hepatic triglycerides, glyoxalase cycle, high-fat high-sucrose diet, diabetic nephropathy, glycolysis, post-translational modifications, knockout mice